Constellation Pharmaceuticals Provides Updates of MANIFEST Study for CPI-0610 and EZH2 Franchise
12 juin 2020 02h30 HE
|
Constellation Pharmaceuticals , Inc.
Spleen response rates in first-line patients at 12 weeks and 24 weeks in line with previously reported data and differentiated from standard of careSpleen responses demonstrated in...
Constellation Pharmaceuticals to Participate in Investor Conference
29 mai 2020 09h00 HE
|
Constellation Pharmaceuticals , Inc.
CAMBRIDGE, Mass., May 29, 2020 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover...
Constellation Pharmaceuticals Announces First-Quarter 2020 Financial Results
06 mai 2020 07h00 HE
|
Constellation Pharmaceuticals , Inc.
EHA abstracts to publish on May 14 with an interim update across the MANIFEST trial cohortsConstellation to provide an additional interim update from MANIFEST at EHA in mid-June Company continues to...
Constellation Pharmaceuticals to Participate in Two Investor Conferences
05 mai 2020 14h06 HE
|
Constellation Pharmaceuticals , Inc.
CAMBRIDGE, Mass., May 05, 2020 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover...
Constellation Pharmaceuticals to Host Conference Call to Discuss First Quarter 2020 Results
28 avr. 2020 09h00 HE
|
Constellation Pharmaceuticals , Inc.
CAMBRIDGE, Mass., April 28, 2020 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop...
Constellation Pharmaceuticals Announces Fourth-Quarter and Full-Year 2019 Financial Results
10 mars 2020 16h12 HE
|
Constellation Pharmaceuticals , Inc.
Clinical data presented at 2019 American Society of Hematology (ASH) annual meeting suggested that CPI-0610 could offer meaningful benefits beyond standard of care in myelofibrosis In addition to...
Constellation Pharmaceuticals to Host Conference Call to Discuss Fourth Quarter 2019 Results
06 mars 2020 13h00 HE
|
Constellation Pharmaceuticals , Inc.
CAMBRIDGE, Mass., March 06, 2020 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel...
Constellation Pharmaceuticals to Present at J.P. Morgan Healthcare Conference
06 janv. 2020 12h33 HE
|
Constellation Pharmaceuticals , Inc.
CAMBRIDGE, Mass., Jan. 06, 2020 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover...
Constellation Pharmaceuticals to Participate in Upcoming Investor Conferences
13 nov. 2019 09h00 HE
|
Constellation Pharmaceuticals , Inc.
CAMBRIDGE, Mass., Nov. 13, 2019 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover...
Constellation Pharmaceuticals Announces Third-Quarter and Nine-Month 2019 Financial Results
06 nov. 2019 09h00 HE
|
Constellation Pharmaceuticals , Inc.
First MANIFEST data showing signs of CPI-0610 clinical activity in JAK-inhibitor-naïve myelofibrosis patients Data showing signs of continuing activity in ruxolitinib-refractory or -intolerant...